Foley is pleased to be a Sponsor of the 27th Annual Moss Adams 2022 Heath Care Conference. Partners Anil Shankar and Lawrence Vernaglia will be speaking and moderating on two different panels at the conference on Thursday, November 3.
Anil Shankar will be moderating the panel “The Urgency of Behavioral Health Integration and Whole Person Care”.
Lawrence Vernaglia will be speaking on the panel “Bonus Lunch Session: Hospital at Home: Where is it at and where is it going?”.
Health care executives—from providers, payors, disrupters, and industry thought-leaders—will converge to discuss the value of transforming health care through collaboration, innovation, and risk-taking.
The conference will address the current state of health care, including:
- Strategies for CFOs to tackle difficult financial challenges
- The future of value-based care and Medicare Advantage
- Methods for operating in a post-pandemic market to leverage strategy, operations, and reimbursement tactics
- Insights to integrate behavioral health as a long-term strategy
- Keynote session with CMS administrators
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.